IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study
Standard
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. / Lawless, Sarah; Sbianchi, Giulia; Morris, Curly; Iacobelli, Simona; Bosman, Paul; Blaise, Didier; Reményi, Péter; Byrne, J L; Mayer, Jiri; Apperley, Jane; Lund, Johan; Kobbe, Guido; Schaap, Nicolaas; Isaksson, Cecilia; Lenhoff, Stig; Basak, Grzegorz; Touzeau, Cyrille; Wilson, Keith M O; González Muñiz, Soledad; Scheid, Christof; Browne, Paul; Anagnostopoulos, Achilles; Rambaldi, Alessandro; Jantunen, Esa; Kröger, Nicolaus; Schönland, Stefan; Yakoub-Agha, Ibrahim; Garderet, Laurent.
In: CL LYMPH MYELOM LEUK, Vol. 21, No. 10, 10.2021, p. 686-693.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study
AU - Lawless, Sarah
AU - Sbianchi, Giulia
AU - Morris, Curly
AU - Iacobelli, Simona
AU - Bosman, Paul
AU - Blaise, Didier
AU - Reményi, Péter
AU - Byrne, J L
AU - Mayer, Jiri
AU - Apperley, Jane
AU - Lund, Johan
AU - Kobbe, Guido
AU - Schaap, Nicolaas
AU - Isaksson, Cecilia
AU - Lenhoff, Stig
AU - Basak, Grzegorz
AU - Touzeau, Cyrille
AU - Wilson, Keith M O
AU - González Muñiz, Soledad
AU - Scheid, Christof
AU - Browne, Paul
AU - Anagnostopoulos, Achilles
AU - Rambaldi, Alessandro
AU - Jantunen, Esa
AU - Kröger, Nicolaus
AU - Schönland, Stefan
AU - Yakoub-Agha, Ibrahim
AU - Garderet, Laurent
N1 - Copyright © 2021 Elsevier Inc. All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - BACKGROUND: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data.PATIENTS: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with "usual" and "rare" myelomas.RESULTS: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis.CONCLUSION: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.
AB - BACKGROUND: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data.PATIENTS: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with "usual" and "rare" myelomas.RESULTS: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis.CONCLUSION: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.
U2 - 10.1016/j.clml.2021.05.012
DO - 10.1016/j.clml.2021.05.012
M3 - SCORING: Journal article
C2 - 34158265
VL - 21
SP - 686
EP - 693
JO - CL LYMPH MYELOM LEUK
JF - CL LYMPH MYELOM LEUK
SN - 2152-2650
IS - 10
ER -